Document:

EX-10.17

 Exhibit 10.17 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 

NON-EXCLUSIVE LICENSE AGREEMENT 

This License (the “Agreement”) is entered into as of August 1, 2019 (the “Effective Date”) by and between Bio-Rad Laboratories, Inc., a Delaware corporation, with a principal business address at 1000 Alfred Nobel Drive, Hercules, CA 94 (“Bio-Rad”) and Biodesix,
Inc., a Delaware corporation, with a principal business address at 2970 Wilderness Place, Suite 100 Boulder, CO 80301, USA (“Biodesix”). Bio-Rad and Biodesix are individually referred to
herein as a “Party” and collectively as the “Parties”. 
 RECITALS 

WHEREAS, Bio-Rad is skilled in the manufacture, marketing and sales of instruments and reagents for
performing digital PCR technology; 
 WHEREAS, Bio-Rad has developed proprietary expertise, know-how, materials, and technology related to certain reagents for performing digital PCR (“dPCR”) technology; 

WHEREAS, Biodesix is skilled and experienced in the provision of cancer detection testing services; 

WHEREAS, Biodesix wishes to obtain a license from Bio-Rad to purchase from Bio-Rad certain dPCR reagents for use by Biodesix in performance of dPCR assay services; and 
 WHEREAS, Bio-Rad desires to provide Biodesix’s requirements for such reagents and license their use to Biodesix for use in performing dPCR using a Bio-Rad Droplet Digital PCR
System and consumables, the reagents, instruments and other consumables to be supplied by Bio-Rad to Biodesix pursuant to that certain Supply Agreement (“Supply Agreement”) having the same
effective date as this Agreement; 
 NOW, THEREFORE, for and in consideration of the mutual covenants and promises set forth herein, the
Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 For purposes of this
Agreement, the following words and phrases shall have the following respective meanings: 
  

	1.1.	 “Affiliate” means, with respect to a Party to this Agreement, any corporation or other legal
entity that controls, is controlled by, or is under common control with such Party. For purposes of this definition, “control” means: 

  

	 	a.	 the ownership, directly or indirectly, of more than fifty percent (50%) of the outstanding voting securities of
a corporation or entity; or 

	 	b.	 the right to receive fifty percent (50%) or more of the profits or earnings of an entity; or

  

	 	c.	 the right to vote for or appoint a majority of the board of directors or other governing body of such entity;
or 

  

	 	d.	 the possession, directly or indirectly, of the power to direct or cause the direction of the management and
policies of such entity. 

  

	1.2.	 “Confidential Information” of a Party means any commercial or technical data, documents,
materials, procedures, and similar information of such Party that is not generally known to the public, including, without limitation, all technology, inventions, records, processes, know-how, non-published patent applications, trade secrets, business plans, research strategies, financial reports, drawings, specifications, equipment and samples, whether in oral or tangible form, that is disclosed by such
Party under this Agreement or is observed at such Party’s facilities during the Term of this Agreement. 

  

	1.3.	 “Contract Services” means the use of a Licensed Instrument together with Licensed Products to
perform digital PCR assays (“dPCR assays”) on a fee-for-service basis for Third Parties, said dPCR assays or use of a Licensed Instrument to perform
dPCR assays being covered by at least one Valid Claim of a Licensed Patent. 

  

	1.4.	 “Field of Use” means the use of Licensed Products to perform Contract Services for oncology
testing. 

  

	1.5.	 “Licensed Instrument” means the Bio-Rad QX100 Droplet
Digital PCR System and the QX200 Droplet Digital PCR System and any other droplet digital PCR instrument or system commercialized by Bio-Rad. 

 

	1.6.	 “Licensed Patents” means the patents listed in Exhibit A. 

 

	1.7.	 “Licensed Products” means reagents, enzymes, buffers, oils, cartridges, gaskets, and other
consumables manufactured by or for Bio-Rad and supplied by Bio-Rad to Biodesix under the Supply Agreement for use in performing Contract Services in accordance with the
terms and conditions of this Agreement and the Supply Agreement. 

  

	1.8.	 “Net Services Fees” means the US$ equivalent of the gross amount invoiced by Biodesix to Third
Parties for the performance of Contract Services, less taxes and discounts allowed and taken, in amounts customary in the trade. 

  

	1.9.	 “Regulatory Approval” means, with respect to the Territory, all approvals, licenses,
registrations, or authorizations by an applicable Regulatory Authority necessary to perform the Contract Services in the Field of Use in the Territory. 

  
 2 

	1.10.	 “Regulatory Authority” means any regulatory authority or governmental entity having the
responsibility, jurisdiction, and authority to approve the manufacture, use, importation, packaging, labeling, marketing, and sale of diagnostic products and medical devices in the Territory. 

 

	1.11.	 “Territory” means the United States, and its territories. 

 

	1.12.	 “Third Party” means a person or entity that is not a Party to this Agreement or an Affiliate
of a Party to this Agreement as of the Effective Date. 

  

	1.13.	 “Valid Claim” means an unexpired claim of a Licensed Patent which has not been held invalid or
unenforceable by a U.S. Court or administrative body and from which no appeal is available or has been taken. 

  

	1.14.	 “Year” and “Quarter” shall mean calendar year and calendar quarter.

 ARTICLE 2 

GRANT AND LIMITATION OF RIGHTS 
  

	2.1.	 Subject to the terms and conditions of this Agreement, Bio-Rad grants
to Biodesix, and Biodesix hereby accepts from Bio-Rad, a non-exclusive license under the Licensed Patents, without the right to grant sublicenses, to use the Licensed
Products to make and use dPCR assays and to use Licensed Instruments and Licensed Products to perform Contract Services and to sell Contract Services in the Field of Use and in the Territory. For the avoidance of doubt, the license granted to
Biodesix under this Section to perform Contract Services is limited to the use of a Licensed Instrument to perform Contract Services. 

  

	2.2.	 Biodesix acknowledges and hereby agrees that Bio-Rad, on behalf of
itself and its Affiliates, reserves all rights in the Field of Use and in the Territory to (i) make, have made, use, offer for sale, sell, have sold and import Licensed Instruments and Licensed Products; and (ii) use Licensed Instruments
and Licensed Products to perform Contract Services or services that are similar to and/or compete with the Contract Services; and (iii) grant licenses or transfer technology to any Third Party as Bio-Rad
may determine in its sole discretion. 

  

	2.3.	 No right or license is granted to Biodesix, either expressly or by implication for any purpose other than as
set forth under paragraph 2.1. 

  

	2.4.	 For the sake of clarity, no right or license is granted to Biodesix under this Agreement to make, have made, or
sell, directly or indirectly, any Licensed Product either individually or together with other products or Licensed Products or any kit containing a Licensed Product. 

  
 3 

 ARTICLE 3 

SUPPLY AGREEMENT 
  

	3.1.	 Biodesix shall purchase its entire requirements of Licensed Instruments and Licensed Products for use in
performing the Contract Services under this Agreement only from Bio-Rad. 

  

	3.2.	 Biodesix shall enter into a Supply Agreement with Bio-Rad pursuant to
which Bio-Rad will supply Licensed Products to Biodesix, the Supply Agreement having an effective date the same as the Effective Date of this Agreement. 

 

	3.3.	 The purchase price for each of the Licensed Products for use in performing the Contract Services shall be the
prices set forth in the Supply Agreement, or such other prices as may be agreed to separately in writing by Biodesix and Bio-Rad. 

ARTICLE 4 
 FEES,
ROYALTIES, AND PAYMENTS 
  

	4.1.	 In further consideration of the rights granted under this Agreement, Biodesix will pay Bio-Rad a royalty of [***] of Net Service Fees. 

  

	4.2.	 Royalties shall be payable in United States dollars, with amounts based on the New York rate of exchange for
the currency of such transactions as quoted in the Wall Street Journal for the last business day of each Quarter for all Net Service Fees received by Biodesix in currencies other than United States dollars. 

 

	4.3.	 Unless otherwise mutually agreed in writing, all payments shall be by one of the following methods:

  

	 	a.	 Wire transfer in U.S. dollars payable to Bio-Rad through

 Bank Name: [***] 

Account Name: [***] 
 Account
Number: [***] 
 Routing number: [***] 

Swift Code: [***] 
 or 

 

	 	b.	 Check in U.S. dollars, payable to Bio-Rad Laboratories, Inc., drawn on
a U.S. bank. 

  

	4.4.	 The written report required pursuant to paragraph 0 shall be sent to: 

Bio-Rad Laboratories, Inc. 

Attn.: Josh Shinoff, PhD 
 Vice
President, Business Development 
 Life Sciences Group & Digital Biology Group 

Bio-Rad Laboratories, Inc. 

5731 West Las Positas Blvd 

Pleasanton, CA 94588 

  
 4 

 
Office [***] 
 Cell [***] 

[***] 
 ARTICLE 5 

REPORTS, RECORDS, AND AUDITS 
  

	5.1.	 Within thirty (30) days following the end of each calendar Quarter during the Term of this Agreement Biodesix
shall send to Bio-Rad a written report substantially in the form attached in Exhibit B, including the following: Net Service Fees during such calendar Quarter, even if there are no Net Service Fees to
report for that Quarter; (iv) a calculation of the royalties due to Bio-Rad under this Agreement. 

  

	5.2.	 Biodesix shall keep complete and correct books of account containing records of all Contract Services performed
and other data in sufficient detail to demonstrate compliance with the terms of this Agreement. Upon Bio-Rad’s request and reasonable notice, Biodesix agrees to permit an independent certified public
accountant selected by Bio-Rad and reasonably acceptable to Biodesix, to have sufficient access for inspection of those books of account during business hours for a one (1) day audit period to verify
compliance with the terms of this Agreement, which inspection shall be made no more often than once in any twelve (12) month period Such independent certified public accountant shall have no financial interest in the outcome of such audit, and shall
attest to this fact, in writing, to Biodesix in advance of the commencement of any such audit. Bio-Rad agrees that all sales and other accounting information made available or disclosed to the independent
certified public accountant under this section shall be treated as Biodesix’s Confidential Information. The costs and expenses related to such inspection shall be borne by Bio-Rad unless the inspection
indicates that Biodesix has reported and paid less than [***] of the full amount of royalties due and owing to Bio-Rad in any Year for any period covered by such inspection, in which case the costs and
expenses shall be borne by Biodesix. If as a result of the inspection, the independent certified public accountant concludes that Biodesix owes additional royalties or other payments under this Agreement, Biodesix shall pay such amounts within
thirty (30) days of its receipt of written notice from Bio-Rad. If as a result of the inspection, the independent certified public accountant concludes that Biodesix has overpaid royalties or other payments
under this Agreement, Biodesix may offset the overage against future payments due under this Agreement. 

 ARTICLE 6

 MANUFACTURING AND QUALITY CONTROL; REGULATORY 
  

	6.1.	 Biodesix shall perform the Contract Services using commercially reasonable standards of care and quality and no
less standards of care and quality than Biodesix uses in the performance of similar services. Biodesix shall comply with all legal and other regulatory requirements relating to the use of the Licensed Products in the Field of Use in the Territory. Bio-Rad shall have the right to visit and inspect the facilities of Biodesix upon reasonable notice and during normal business hours and no more than once per year unless a finding is made about a visit or
inspection that requires follow-up or correction. 

  
 5 

	6.2.	 Biodesix shall have the sole right and responsibility, at its expense, for preparing, filing, pursuing, and
maintaining all regulatory filings, including, without limitation, labeling required to be filed with Regulatory Authorities, to obtain approval for provision of the Contract Services, and for seeking Regulatory Approvals with respect to such
Contract Services in the Territory. All such Regulatory Approvals and applications thereof shall be owned by Biodesix. In addition, Biodesix shall have sole control over all communications with Regulatory Authorities, including, without limitation,
filings with Regulatory Authorities, with regard to the Contract Services. Biodesix shall provide Bio-Rad promptly with a copy of all Regulatory Approvals of the Contract Services. Bio-Rad will provide reasonable assistance to Biodesix in support of its application for regulatory approval of the Contract Services in the form of supplying documentation relating to the Licensed Product(s) to
Biodesix or the applicable Regulatory Authorities, at Bio-Rad’s sole discretion. 

  

	6.3.	 Biodesix shall be responsible for all customer service to all Third Parties receiving the Contract Services.

 ARTICLE 7 

PROPRIETARY RIGHTS 
  

	7.1.	 Each Party owns and retains all right, title, and interest in and to such Party’s intellectual property
rights (“IP”) and Confidential Information. Except as expressly set forth in this Agreement, neither Party grants to the other any license to its IP. “IP” means any and all intellectual property of any nature owned or
controlled by a Party or its Affiliates prior to the Effective Date, or intellectual property that arises during the Term of this Agreement and is owned or controlled by such Party or its Affiliates after the Effective Date. 

 

	7.2.	 Use by Biodesix of Bio-Rad’s trademarks, tradename, and logo
(“Marks”) are governed by Sections 10.3-10.7 of the Agreement. 

  

	7.3.	 Biodesix shall not change or modify in any way any Bio-Rad Mark which
is used by Bio-Rad on the Licensed Product(s) or in any product inserts, advertisements and sales literature when referring to the Licensed Product(s). Bio-Rad’s
Marks shall be properly used and Biodesix shall acknowledge Bio-Rad’s ownership of the Bio-Rad Marks when so used. Biodesix shall not use any Bio-Rad Mark as part of the name under which Biodesix conducts its business, or any connected business, or under which it markets or sells Contract Services or in any way which is harmful or derogatory to Bio-Rad. Upon termination of this Agreement for any reason, Biodesix will immediately stop using all or any part of any Bio-Rad Marks. 

 

	7.4.	 Biodesix shall not advertise, promote, or sanction any use of the Licensed Products other than for use in the
Field of Use. Biodesix shall institute reasonable procedures to discourage and/or report unauthorized use of the Licensed Products. 

  

	7.5.	 Biodesix shall not register, nor attempt to register, nor aid any Third Party in the registration of any Bio-Rad Marks. Except as expressly granted under this Agreement, no right or license is granted to Biodesix to use Bio-Rad’s Marks. 

  
 6 

	7.6.	 Biodesix understands and agrees that use of Bio-Rad’s Marks in
connection with the Licensed Products shall not create any right, title, or interest, in or to the trademarks, and that all uses and goodwill associated with Bio-Rad’s Marks will inure to the benefit of Bio-Rad. 

  

	7.7.	 Prosecution of a Third Party for the infringing use of Bio-Rad’s
Marks, copyrights or patents may be undertaken by Bio-Rad at its option. Biodesix shall provide information reasonably requested by Bio-Rad in connection with such
matters. 

 ARTICLE 8 

CONFIDENTIALITY 
  

	8.1.	 Each Party agrees to maintain Confidential Information received from the other Party with the same degree of
care it uses to protect its own Confidential Information, and each Party represents that it exercises reasonable care to protect its own Confidential Information. Each Party agrees not to use the Confidential Information of the other Party for any
purpose other than performing its obligations under this Agreement. 

  

	8.2.	 Biodesix agrees to maintain in confidence and not to disclose to any Third Party, either during or for [***]
years subsequent to the term of this Agreement, any Confidential Information with respect to the product formulations, chemical names or structures, manufacturing procedures, pricing, marketing, patenting, or other aspects of Licensed Products, and
the manner in which Bio-Rad conducts its business. 

  

	8.3.	 Information received by one Party from the other Party will be deemed not to be Confidential Information of the
disclosing Party to the extent, and only to the extent, that it: 

  

	 	a)	 is now or hereafter becomes generally known or available to the public without the receiving Party’s
breach of any obligation owed to the disclosing Party; or 

  

	 	b)	 is independently developed by the receiving Party and can be so documented, or was acquired by the receiving
Party before receiving such information from the disclosing Party under this Agreement, without restriction as to use or disclosure and can be so documented; or 

 

	 	c)	 is hereafter rightfully furnished to the receiving Party under this Agreement by a Third Party without any
breach of an obligation of confidentiality to the disclosing Party and without restriction on use or disclosure; or 

  

	 	d)	 is disclosed by the receiving Party with the prior written consent of the disclosing Party.

  

	8.4.	 Notwithstanding paragraph 0, any specific combination of individual aspects of information will not be deemed
known prior to disclosure merely because the individual aspects of information were previously known; and uses of certain materials will not be deemed known merely because the materials themselves were previously known. 

  
 7 

	8.5.	 A receiving Party may disclose Confidential Information if required to do so by applicable law, an
administrative or court order, or governmental regulation; provided that the receiving Party promptly notify the disclosing Party when it learns that disclosure may be required, and the receiving Party shall take reasonable action to avoid the
disclosure or limit its scope. Any information disclosed pursuant to this paragraph 0 will remain the Confidential Information of the disclosing Party and subject to this Agreement. 

 

	8.6.	 Either Party may, without the prior written consent of the other, disclose the terms of this Agreement to Third
Parties under substantially the same terms as paragraphs 0 through 0 of this Agreement solely for the purpose of due diligence for a public offering, private placement, financing, acquisition or merger. Any information disclosed pursuant to this
paragraph 0 will remain the Confidential Information of the disclosing Party and subject to this Agreement. 

  

	8.7.	 The Parties will cooperate with each other regarding any media release or similar public announcement relating
to this Agreement or its subject matter and will give the other Party an opportunity to review and approve the content of each such release or announcement prior to its release. Notwithstanding the above, Biodesix shall not issue any such media
release or public announcement with respect to this Agreement without Bio-Rad’s review and prior written consent. 

 

	8.8.	 No Confidential Information of either Party shall be published by the receiving Party without written
permission from the other. 

 ARTICLE 9 

WARRANTIES 
  

	9.1.	 Each Party represents and warrants to the other that (a) it is a company or corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction in which it is organized; (b) it has the legal power and authority to execute, deliver and perform this Agreement; (c) the execution, delivery and performance by it
of this Agreement has been duly authorized by all necessary corporate action; (d) this Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms; and (e) the
execution, delivery and performance of this Agreement will not cause or result in a violation of any law or of such Party’s charter documents. 

  

	9.2.	 Biodesix represents and warrants that it is solely responsible for obtaining all intellectual property rights,
including but not limited to all assay-specific licenses, required to permit Biodesix to exercise the rights granted to it under this Agreement; and to the best of Bio-Rad’s knowledge the Licensed IP is
valid. 

  

	9.3.	 Bio-Rad warrants that all Licensed Products delivered under this
Agreement will substantially conform at the time of shipment to the specifications set forth in the product insert. 

  

	9.4.	 EXCEPT FOR THE EXPRESS WARRANTIES STATED IN THIS AGREEMENT, BIO-RAD
MAKES NO ADDITIONAL WARRANTIES, EXPRESS OR IMPLIED OR STATUTORY, AS TO ANY MATTER WHATSOEVER. IN PARTICULAR, AND ANY 

  
 8 

	 	
AND ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY EXCLUDED. BIODESIX SHALL NOT HAVE THE RIGHT TO MAKE OR PASS ON, AND SHALL TAKE ALL MEASURES NECESSARY TO
ENSURE THAT NEITHER IT NOR ANY OF ITS AGENTS, EMPLOYEES, AFFILIATES OR DISTRIBUTORS, OR AGENTS OR EMPLOYEES THEREOF MAKE OR PASS ON, ANY SUCH WARRANTY OR REPRESENTATION ON BEHALF OF BIO-RAD TO ANY CUSTOMER OF
BIODESIX CONTRACT SERVICES, OR ANY OTHER THIRD PARTY. 

 ARTICLE 10 

LIMITATION OF LIABILITES 
  

	10.1.	 NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, BIO-RAD
SHALL NOT UNDER ANY CIRCUMSTANCES, BE LIABLE TO BIODESIX FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL OR EXEMPLARY DAMAGES OF ANY KIND, ARISING OUT OF OR RELATED TO BIODESIX’S EXERCISE OF THE RIGHTS GRANTED TO IT UNDER THIS AGREEMENT, INCLUDING
BUT NOT LIMITED TO LOST PROFITS OR LOSS OF BUSINESS, EVEN IF BIO-RAD IS APPRISED OF THE LIKELIHOOD OF SUCH DAMAGES OCCURRING. 

 

	10.2.	 EXCEPT FOR CLAIMS ARISING FROM SECTIONS 8 AND 11.3, BIO-RAD’S
TOTAL LIABILITY OF ALL KINDS ARISING OUT OF OR RELATED TO THIS AGREMENT, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY CLAIMS HEREUNDER, REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT (INCLUDING
NEGLIGENCE), STRICT PRODUCT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED THE TOTAL AMOUNT PAID BY BIODESIX TO BIO-RAD HEREUNDER (DETERMINED AS OF THE DATE OF ANY FINAL JUDGMENT IN SUCH ACTION).

  

	10.3.	 IT IS EXPRESSLY UNDERSTOOD AND AGREED THAT EACH AND EVERY PROVISION OF THIS AGREEMENT WHICH PROVIDES FOR A
LIMITATION OF LIABILITY, DISCLAIMER OF WARRANTIES OR EXCLUSION OF DAMAGES, IS INTENDED BY THE PARTIES TO BE SEVERABLE AND INDEPENDENT OF ANY OTHER PROVISION AND TO BE ENFORCED AS SUCH. 

 

	10.4.	 Biodesix understands that, although no specific hazards have been identified in connection with the use of the
Product(s), the Product(s) should be used with the same protective measures and degree of caution used with any chemical compound whose hazardous nature is unknown. 

ARTICLE 11 

INDEMNIFICATION 
  

	11.1.	 Subject to Section 11.2, Biodesix agrees to indemnify, defend and hold harmless Bio-Rad and its directors, officers, employees, and agents, from and against any and all Third Party 

  
 9 

	 	
liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees and other costs of litigation), losses or causes of action (each,
“Liability”) arising out of or relating in any way to its possession, use (either for its internal use or use in connection with performing Contract Services) by or on behalf of Biodesix, or its Affiliates, whether based on breach
of warranty, negligence, product liability or otherwise. Bio-Rad agrees to indemnify, defend and hold harmless Biodesix and its directors, officers, employees, and agents, from and against any and all Third
Party liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees and other costs of litigation), losses or causes of action (each, “Liability”) resulting from Bio-Rad’s negligence or misconduct. 

  

	11.2.	 Biodesix shall indemnify, defend and hold harmless Bio-Rad and its
directors, officers, employees, and agents, from and against any and all Liabilities to the extent arising from any alleged or actual infringement of a Third Party’s patent, copyright or other proprietary rights (“Claim”) arising from
Biodesix’s exercise of the rights granted to it under this Agreement, including the performance of the Contract Services. Notwithstanding the foregoing, Biodesix will not be obligated to indemnify or defend
Bio-Rad or be liable for any Liabilities to the extent the alleged infringement arises solely from the Licensed Products as supplied by Bio-Rad to Biodesix under the
Supply Agreement and excluding any use of the Licensed Products by Biodesix in combination with any other materials, including any reagents not supplied by Bio-Rad, or other technology. 

 

	11.3.	 Bio-Rad shall indemnify, defend and hold harmless Biodesix and its
directors, officers, employees, and agents, from and against any and all Liabilities to the extent arising from any Claim arising from Biodesix’s use of a Licensed Instrument to perform Contract Services pursuant to and in accordance with the
terms and conditions of this Agreement, except to the extent that such Claim arises from (i) Biodesix’s use of third-party materials or processes in the performance of dPCR assays, (ii) Biodesix’s performance of dPCR assays using
a protocol other than Bio-Rad’s published protocols for such assays; or (iii) biomarkers which are targeted by a dPCR assay. 

ARTICLE 12 
 TERM AND
TERMINATION 
  

	12.1.	 The initial term of this Agreement shall be from the Effective Date of this Agreement until five (5) years
from the Effective Date. At the end of the Initial Period, this Agreement shall terminate, unless both Parties agree to renew this Agreement prior to the end of initial term. The initial term and any extension period are referred to collectively as
the “Term”. 

  

	12.2.	 In the event that Biodesix does not purchase any Licensed Product(s) pursuant to the terms of the Supply
Agreement for a consecutive [***] month period, or in the event of any other material breach of the Supply Agreement by Biodesix, Bio-Rad may, at its election, terminate this Agreement upon [***] days prior
written notification to Biodesix according to paragraph 14.1. Any failure to terminate hereunder shall not be considered as a waiver by Bio-Rad of its right to terminate for any future default or breach.

  
 10 

	12.3.	 If either Party defaults on or breaches any material term of this Agreement, the aggrieved Party may give
written notice of the alleged default or breach to the other Party. If such default or breach is not remedied or resolved during the dispute resolution period as set forth in Article 14, the aggrieved Party may, at its election, terminate this
Agreement immediately upon written notice. Any failure to terminate hereunder shall not be considered as a waiver by the aggrieved Party of its right to terminate for any future default or breach. 

 

	12.4.	 If either Party becomes insolvent or makes an assignment for the benefit of creditors, or if proceedings for
voluntary bankruptcy are instituted on behalf of either Party, or if either Party is declared bankrupt or insolvent, the other Party may, at its election, terminate this Agreement immediately by giving written notice of termination to the bankrupt
or insolvent Party. 

  

	12.5.	 Termination of this Agreement for any reason shall not release any Party hereto from any liability which, at
the time of such termination, has already accrued to the benefit of the other Party or which is attributable to a period prior to such termination nor preclude any Party from pursuing any rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement. 

  

	12.6.	 Upon any termination of the Agreement, Bio-Rad and Biodesix shall
promptly return to the disclosing Party, at its request, all Confidential Information of the disclosing Party, or verification by an authorized signatory of the receiving Party that all such Confidential Information was destroyed. However, one copy
may be retained in the receiving Party’s legal files. 

  

	12.7.	 Articles 1, 9, 10, 11, 12, and 13, paragraphs 12.50 and 15.6, and this paragraph shall survive the
expiration or termination of this Agreement for any reasons. 

 ARTICLE 13 

NOTICE 
  

	13.1.	 Any notices required or permitted to be given under this Agreement shall be: 

 

	 	a.	 	sent by e-mail, and 

  

	 	b.	 	confirmed by a letter delivered to the other Party by a reputable international express courier service (for example: DHL, Federal Express or similar organizations), properly addressed to the Party to receive the same
at the address indicated below, or to such other address as either Party may designate by proper, written notice to the other: 

  

			
	If to Bio-Rad:	    	Digital Biology Group
		    	Bio-Rad Laboratories, Inc.
		    	5731 West Las Positas Blvd.
		    	Pleasanton, CA, USA 94588
		    	Attn: [***]
		    	Email: [***]

  
 11 

			
		
	With a copy to:	    	Office of the General Counsel
		    	Bio-Rad Laboratories, Inc.
		    	1000 Alfred Nobel Drive
		    	Hercules, CA, USA 94547
		
	If to BIODESIX:	    	Biodesix, Inc.
		    	2970 Wilderness Place,
		    	Suite 100 Boulder,
		    	CO 80301, USA
		    	Attn: Legal Affairs
		    	Email: LegalAffairs@Biodesix.com

 Notices shall be deemed to have been given upon receipt of the email or upon confirmation of the delivery of
the letter, whichever is evidenced to be the earlier. 
  

	13.2.	 Any Party may change its designated address and facsimile number by notice to the other Party in the manner
provided in this Article. 

 ARTICLE 14 

DISPUTE RESOLUTION 
  

	14.1.	 In the event either Party claims breach of this Agreement, the Parties shall consult with each other in good
faith on the most effective means to cure the breach and to achieve any necessary restitution of its consequences. This consultation shall be undertaken within a period of [***] days following the receipt of a written request to consult, and the
consultation period shall not exceed [***] days. During the consultation period, neither litigation nor arbitration may be pursued until attempts at consultative dispute resolution in accordance with this Section 14.1 have been exhausted.

 ARTICLE 15 

MISCELLANEOUS 
  

	15.1.	 Benefit and Assignment. Neither this Agreement nor any rights or benefits hereunder shall be
assignable or transferable by Biodesix or its Affiliates without the prior written consent of Bio-Rad, except for an assignment resulting from an acquisition or sale of substantially all of Biodesix’s
assets relating to this Agreement. Any assignment by Biodesix not in accordance with this paragraph shall be void. Bio-Rad may assign this Agreement without prior written consent of Biodesix.

  

	15.2.	 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the successors
and permitted assigns of the Parties. 

  

	15.3.	 Governing Law and Venue. This Agreement and all matters connected with the performance thereof
shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard to conflict of law provisions. 

  
 12 

	15.4.	 Prior Agreements. This Agreement together with the Exhibits hereto, sets forth the entire
understanding between the Parties with respect to the matters dealt with herein and supersedes any and all prior Agreements, written or oral, previously entered into by the Parties covering the matters dealt with herein. No modification of any of
the provisions contained herein may be made except in writing, in each instance signed by and on behalf of the Party against which enforcement shall be sought hereof. It is expressly understood and agreed that no employee, agent or other
representative of the Parties has any authority to bind the Parties with respect to any statement, representation, warranty or other expression unless the same is specifically set forth in this Agreement. 

 

	15.5.	 Interpretation. It is understood and agreed to that no usage of trade or other regular practice
or method of dealing between the Parties hereto shall be used to modify, interpret, supplement or alter in any manner the terms of this Agreement. Acceptance or acquiescence in a course of performance under this Agreement shall not be relevant to
determine the meaning of this Agreement even though the accepting or acquiescing Party had knowledge of the nature of the performance and opportunity for objection. 

 

	15.6.	 Severability. The Parties do not intend to violate any public policy or statutory or common law.
However, if any sentence, paragraph, clause or combination thereof of this Agreement is in violation of any law or is found to be otherwise unenforceable by a court or competent administrative body from which there is no appeal, or no appeal is
taken, such sentence, paragraph, clause, or combination thereof shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the commercial or economic terms of this Agreement. The Parties
shall negotiate in good faith to substitute for any such invalid or unenforceable provision, a valid and enforceable provision that achieves to the greatest extent possible the economic, legal and commercial objectives of the invalid or
unenforceable provision. 

  

	15.7.	 Waivers and Amendments. No change, modification, extension, or waiver of this Agreement, or any
of the provisions herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the Parties hereto. 

  

	15.8.	 Waiver. No delay on the part of either Party hereto in exercising any power or right hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power or right. No waiver of this Agreement or any provision hereof
shall be enforceable against any Party hereto unless in writing, signed by the Party against whom such waiver is claimed, and any such waiver shall be limited solely to the one event. 

 

	15.9.	 Force Majeure. Any failure or delay in performance (other than to pay money when due), by either
Party to this Agreement, caused by an event beyond the reasonable control of either Party shall not be deemed a breach of this Agreement, such causes including, but not limited to: acts of God or the public enemy; war; riots; insurrections and other
hostilities; fires; explosions; floods; acts of governments or government agencies; unavailability of transportation or raw materials; and strikes or other labor disturbances. On occurrence of any such event, the Party whose performance is affected
shall promptly give written notice to the other of the occurrence and its best estimate of the extent to which and length of time 

  
 13 

	 	
the Party’s performance may be prevented, interfered with or delayed. The Term of this Agreement shall then be suspended for a period of time equal to the total period of delay in
performance. If the period of suspension of this Agreement shall last for a period of three (3) months, the Party not affected by such event shall be entitled to terminate this Agreement by providing at least one (1) month notice.

  

	15.10.	 Export Compliance. The Parties agree that each shall not knowingly export or re-export, directly or indirectly, any information, technical data, samples, materials, or equipment received or generated hereunder in violation of any applicable United States government regulations, including but
not limited to Part 779 of the United States Department of Commerce Export Control Regulations. 

  

	15.11.	 Independent Contractors. Nothing in this Agreement is intended nor is to be construed as to
constitute the Parties as partners, joint venturers, or of principal and agent with respect to this Agreement. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the
other Party or to bind the other Party to any other contract, agreement, or undertaking with any Third Party. 

  

	15.12.	 Payments. All dollar ($) amounts stated in this Agreement shall be in the currency of the United
States of America. 

  

	15.13.	 Headings. The Article and paragraph headings contained herein are for the purposes of convenience
of reference only and are not intended to define or limit the contents of said Articles or paragraphs. 

  

	15.14.	 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. The undersigned represent and warrant that they are duly authorized to execute this Agreement and thereby bind their respective Party and that all required
approvals have been obtained. 

  

	15.15.	 Exhibit Incorporation. All Exhibits cited herein are incorporated by reference and made a part of
this Agreement. 

 [Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by
their duly authorized representatives, which Agreement shall be binding on the Parties as of the Effective Date. 
  

							
	Bio-Rad Laboratories, Inc.	 	Biodesix, Inc.
				
	By:	 	 /s/ Josh Shinoff
	 	By:	 	 /s/ Robin Harper Cowie

	Name:	 	 Josh Shinoff
	 	Name:	 	 Robin Harper Cowie

	Title:	 	 Vice President, Business Development, LSG & DBG
	 	Title:	 	 CFO

  
 15 

 EXHIBIT B 

Form of Royalty Report 
  

							
	 Date (Date Range)
 of Contract
Services
 provided
	  	 Description/Type of
 Contract
Services
 Performed
	  	Net Services Fees	  	 Royalty Due to Bio-

Rad

  
 16EX-10.18

 Exhibit 10.18 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS 

BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF 

PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 

EXECUTION VERSION 
 SUPPLY
AGREEMENT 
 between 

BIODESIX, INC. 
 and 

ONCIMMUNE LIMITED 
 dated
as of 
 October 31, 2019 

 THIS AGREEMENT is dated October 31, 2019 (Closing Date) 

BETWEEN 
  

	(1)	 ONCIMMUNE LIMITED, a private limited company incorporated under the laws of England and Wales
(Oncimmune or Supplier); and 

  

	(2)	 BIODESIX, INC., a Delaware corporation (Biodesix). 

RECITALS 
  

	(A)	 Oncimmune carries on the business of manufacturing certain coated plates and other reagents for use in
the Test, and 

  

	(B)	 Biodesix wishes to buy, and Oncimmune wishes to supply, the Product on the terms and conditions set out in this
Agreement. 

 IT IS HEREBY AGREED 
  

	1.	 INTERPRETATION 

 

	1.1	 The following definitions and rules of interpretation in this clause apply in this Agreement.

 Agreement: this Supply Agreement. 

APA: that certain Asset Purchase Agreement, dated as of June 27, 2019, by and between Oncimmune and Biodesix. 

Biodesix Indemnitees: has the meaning given in clause 12.1. 

Business Day: a day, other than a Saturday, Sunday or public holiday in London, England, or New York, New York, when banks in London and
New York are open for business. 
 Claim: any action made or brought by a person entitled to indemnification under clause 12. 

Closing Date: October 31, 2019. 

Cost of Goods: has the meaning given in clause 9.2. 

Commercially Reasonable Efforts: with respect to Supplier only, those efforts that are consistent with the efforts and resources
that would typically be used by a molecular diagnostic company of similar size to Supplier in the exercise of its reasonable business discretion relating to the production of a commercialized diagnostic product, recognising that Oncimmune is not an
established contract manufacturer but is a small research and development company. 
 Delivery Date: the anticipated date for delivery
of Products notified to Biodesix in accordance with clause 4.4.4. 

  
 1 

 Forecast: with respect to the following [***]-month period, a good faith forecast of
Biodesix’s anticipated demand for Product for each calendar month during the period, which approximates, as nearly as possible, based on information available at the time to Biodesix, the Orders Biodesix reasonably expects to place in
these future calendar months. 
 Kansas Lab: the CLIA-licensed laboratory at 8960 Commerce Drive, Building #6, De Soto, Kansas
66018, USA. 
 Losses: has the meaning given in clause 12.1. 

Oncimmune Indemnitees: has the meaning given in clause 12.2. 

Order Number: the reference number to be applied to an Order by Oncimmune in accordance with clause 4.4. 

Personnel: agents, employees, contractors or subcontractors engaged or appointed by Oncimmune or Biodesix, as the case may be. 

PCA: that certain Purchase and Commercialization Agreement, dated as of June 27, 2019, by and between Oncimmune and Biodesix. 

Product: the product set out in Schedule 1, and referred to in multiple quantities as Products. 

Price: has the meaning given in clause 9.1. 

Purchase Order: purchase order for Product submitted by Biodesix in accordance with clause 4. 

Representatives: a party’s affiliates, employees, officers, directors, partners, shareholders, agents, attorneys, third-party
advisors, successors and permitted assigns. 
 Supplier: Oncimmune Limited. 

Supply Failure means the failure during any rolling [***]-month period, to deliver [***] of the Product the subject of Purchase Orders
over that [***]-month period within [***] days of the expected Delivery Date. 
 Term: the term of the Agreement, as determined
in accordance with clause 15.1. 
 Test: has the meaning set forth in the PCA. 

Third-Party Claim: has the meaning given in clause 12.1. 

VAT: value added tax, or any equivalent tax, chargeable in the UK or elsewhere. 

 

	1.2	 Clause, Schedule and paragraph headings shall not affect the interpretation of this Agreement.

  
 2 

	1.3	 A person includes a natural person, corporate or unincorporated body (whether or not having separate
legal personality). 

  

	1.4	 The Schedules form part of this Agreement and shall have effect as if set out in full in the body of this
Agreement and any reference to this Agreement includes the Schedules. 

  

	1.5	 Unless the context otherwise requires, words in the singular shall include the plural and vice versa.

  

	1.6	 Unless the context otherwise requires, a reference to one gender shall include a reference to the other
genders. 

  

	1.7	 This Agreement shall be binding on, and enure to the benefit of, the parties to this Agreement and their
respective personal representatives, successors and permitted assigns, and references to any party shall include that party’s personal representatives, successors and permitted assigns. 

 

	1.8	 A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time. 

  

	1.9	 A reference to a statute or statutory provision shall include all subordinate legislation made from time to
time under that statute or statutory provision. 

  

	1.10	 A reference to writing or written includes fax and email. 

 

	1.11	 Any obligation in this Agreement on a Party not to do something includes an obligation not to agree or allow
that thing to be done by any person. 

  

	1.12	 References to a document in agreed form are to that document in the form agreed by the parties and
initialled by or on their behalf for identification. 

  

	1.13	 References to clauses and Schedules are to the clauses and Schedules of this Agreement. 

 

	1.14	 Any words following the terms including, include, in particular, for example or any
similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms. 

 

	2.	 SUPPLY OF THE PRODUCT 

 

	2.1	 During the Term, Oncimmune shall supply, and Biodesix shall purchase, such quantities of Product as Biodesix
may order pursuant hereto in accordance with the terms and conditions of this Agreement. 

  

	2.2	 Biodesix shall not, and shall not allow any Personnel, affiliate or any other person on its behalf to, copy,
reverse engineer, disassemble, decompile or modify the Product or use the Product other than in the Field in the Territory (as such terms are defined in the PCA). 

  
 3 

	3.	 FORECASTS 

 

	3.1	 Biodesix shall deliver Forecasts to Oncimmune on a rolling monthly basis during the Term. Biodesix shall
deliver the first Forecast within [***] days of the date hereof, and all subsequent Forecasts shall be delivered on or before the last Business Day of each calendar month. With respect to Forecasts for the Product, the initial month of the Forecast
period shall be binding, with the remaining months being advisory and non-binding. Forecasts shall be given in writing or, if given orally, shall be confirmed in writing within [***] Business Days.

  

	3.2	 Forecasts provided under this clause 3 shall not constitute Orders. Other than as set forth in clause 3.1,
Forecasts provided hereunder shall not be binding but shall be Biodesix’s good faith best estimate of its anticipated requirements. 

  

	4.	 ORDERS 

 

	4.1	 Not less than [***] days before the beginning of each calendar month during the Term, Biodesix shall send
Oncimmune its Purchase Order for that calendar month, which Purchase Order shall take into account the binding element of the Forecast. 

  

	4.2	 Oncimmune shall use diligent efforts to supply the Product in accordance with Biodesix’s Purchase Orders,
except that, to the extent that a Purchase Order exceeds the most recent Forecast provided to Oncimmune in accordance with clause 3.1, Oncimmune shall only be obliged to use its Commercially Reasonable Efforts to supply any Product ordered in excess
of such Forecast (and shall not be under any obligation to supply the Product ordered in excess of Forecasts if Biodesix’s demand exceeds Oncimmune’s production capacity). If Oncimmune anticipates at any time that it will not be able to
fulfill for any reason any Purchase Order for the Product in full, then Oncimmune agrees to notify Biodesix of that fact and of the quantities it expects to deliver as soon as practicable. 

 

	4.3	 Each Purchase Order shall: 

 

	 	4.3.1	 be given in writing or, if given orally, shall be confirmed in writing within [***] Business Days;

  

	 	4.3.2	 state a unique Purchase Order number 

 

	 	4.3.3	 specify quantity, description and manufacturer’s part number of Product ordered; and

  

	 	4.3.4	 be delivered at Oncimmune’s contracted manufacturer, Fortress Diagnostics, Unit 2C, Antrim Technology
Park, Antrim, Co. Antrim, BT41 1QS. 

  

	4.4	 Oncimmune shall: 

  

	 	4.4.1	 assign an Order Number to each Purchase Order received from Biodesix; 

  
 4 

	 	4.4.2	 notify Biodesix within [***] Business Days of its acceptance of such Purchase Order (if accepted, or otherwise
of rejection of such Purchase Order, and the reason for such rejection) 

  

	 	4.4.3	 notify Biodesix of the assigned Order Number. 

 

	 	4.4.4	 specify the Delivery Date by which Oncimmune expects the Products ordered to be delivered to Biodesix.

  

	4.5	 Each party shall use the relevant Order Number in all subsequent correspondence relating to the Purchase Order.

  

	4.6	 Biodesix may within [***] days of placing a Purchase Order amend or cancel its Purchase Order by written notice
to Oncimmune. If Biodesix amends or cancels a Purchase Order, its liability to Oncimmune shall be limited to payment to Oncimmune of all costs reasonably incurred by Oncimmune in fulfilling the Purchase Order up until the date of receipt of the
notice of amendment or cancellation. 

  

	5.	 MANUFACTURE, QUALITY AND PACKING

  

	5.1	 Oncimmune shall use Commercially Reasonable Efforts to ensure its contracted manufacturer maintains sufficient
manufacturing capacity, stocks of raw materials and packaging, to enable it to meet Biodesix’s Forecasts. 

  

	5.2	 Oncimmune shall use Commercially Reasonable Efforts to ensure its contracted manufacturer manufactures, packs
and supplies the Product in accordance with all applicable laws and written specifications for the Product. 

  

	5.3	 The Products supplied to Biodesix by Oncimmune under this Agreement shall: 

 

	 	5.3.1	 conform to their respective written specifications; 

 

	 	5.3.2	 be free from defects in design, material and workmanship; and 

 

	 	5.3.3	 be submitted for delivery with a shelf life of no less than [***] months. 

 

	5.4	 Oncimmune shall obtain and maintain in force for the Term all licences, permissions, authorisations, consents
and permits needed to manufacture and supply the Product in accordance with the terms of this Agreement, and Biodesix shall obtain and maintain in force for the Term all licences, permissions, authorisations, consents and permits needed to accept,
import, store and sell the Product in accordance with the terms of this Agreement, the PCA and as necessary to perform the Test and operate the Business (in each case, as defined in the APA). 

 

	5.5	 Subject to the terms of the PCA, the Parties hereby agree and acknowledge that in the event of a Supply
Failure, the applicable minimum sales commitments set forth in Sections 5.3 and 5.4 of the PCA shall be suspended and upon resolution of the Supply Failure, both 

  
 5 

	 	
Parties will reassess future sales prospects in good faith based on an assessment of the commercial impact of the Supply Failure and shall in good faith adjust the minimum sales commitments for
the relevant period, taking into account the nature and extent of the Supply Failure. 

  

	5.6	 In the event that Supplier delivers greater than [***] of the Product that is the subject of Purchase Orders
over an applicable [***]-month period within [***] days of the expected Delivery Date but fails to deliver [***] of such Product, and the failure by Supplier to deliver [***] of the Product as described directly causes Biodesix to fail to meet the
applicable minimum sales commitments set forth in Sections 5.3 and 5.4 of the PCA, then the parties will discuss in good faith an adjustment to the minimum sales commitments. For the avoidance of doubt, in the event that the circumstances
described in this clause 5.6 occur, Sections 5.3 and 5.4 of the PCA shall not be suspended and will remain in full force and effect. 

  

	6.	 DELIVERY 

 

	6.1	 Oncimmune shall use Commercially Reasonable Efforts to deliver the Product within [***] days of the Delivery
Date, and Biodesix shall accept delivery of all ordered Product delivered within such period. 

  

	6.2	 Each delivery of Product shall be accompanied by a line item delivery note from Oncimmune showing the Order
Number, Purchase Order Number, Product lot number(s), Product expiration date(s), the date of the Order and the description, quantity and manufacturer’s part number of Products included in the Order. 

 

	6.3	 If Oncimmune requires Biodesix to return any packaging materials to Oncimmune, that fact must be clearly stated
on the delivery note accompanying the relevant Order, and any such returns shall be at Oncimmune’s expense. 

  

	7.	 DEFECTIVE PRODUCT 

 

	7.1	 If any batch of Products delivered to Biodesix is not in conformity with the terms of this Agreement, including
the terms of clause 5.2, then, without limiting any other right or remedy that Biodesix may have, Biodesix may reject such batch within [***] Business Days of delivery (in the case of defects that are not latent defects) or [***] Business Days of
discovery of the defect in the case of latent defects and require Oncimmune to replace the rejected batch at Oncimmune’s risk and expense within a reasonable time of being requested to do so. The terms of this Agreement shall apply to any such
replacement Products supplied by Oncimmune. 

  

	8.	 TITLE AND RISK 

 

	8.1	 Product shipped under this Agreement will be FCA Incoterms 2010 Seller’s (or its applicable
manufacturer’s) facility, Unit 2C, Antrim Technology Park, Antrim, Co. Antrim, BT41 1QS Northern Ireland (or such other address as Oncimmune may notify Biodesix of in writing from time to time). 

  
 6 

	8.2	 Notwithstanding any other agreement between Oncimmune and Biodesix concerning transfer of title or
responsibility for risk of loss, title to Product shipped under any this Agreement passes to Biodesix as set forth in clause 8.1. 

  

	9.	 PRODUCT PRICE 

 

	9.1	 Oncimmune shall provide Product to Biodesix for an initial price of [***] per Test, as such price may be
updated from time to time in accordance with clause 9.2 (the “Price”). 

  

	9.2	 The Price shall be subject to an increase (not more than once per annum), effective on each anniversary of the
Closing Date, relating to increases in Oncimmune’s documented external cost of goods for raw materials necessary to manufacture the Product (Cost of Goods). Each increase will be limited to the amount of increase in Oncimmune’s Cost
of Goods and will, in any event, be capped at [***] each year. In no event will the Price be subject to any decrease. Oncimmune will provide reasonable documentation for any increased Price resulting from an increased Cost of Goods. Oncimmune will
notify Biodesix in writing of any updated Price no less than [***] days in advance of such increased Price taking effect. 

  

	9.3	 The Price is exclusive of amounts in respect of VAT or other taxes, if applicable. Biodesix shall, on receipt
of a valid VAT invoice from Oncimmune, pay to Oncimmune such additional amounts in respect of VAT as are chargeable on a supply of the Product. 

  

	9.4	 Oncimmune is solely responsible for all costs and expenses relating to packing, crating, boxing, and loading of
the Product at the applicable source facility, and Biodesix is responsible for all costs and expenses relating to freight (including costs and expenses relating to cooling or temperature control of the Product in transit), unloading, customs, taxes,
tariffs and duties, insurance and any other similar financial contributions or obligations, along with any other costs and expenses incurred with respect to the Product once Biodesix takes possession, risk or title to such Product in accordance
herewith. 

  

	10.	 TERMS OF PAYMENT 

 

	10.1	 Oncimmune shall invoice Biodesix for each Order on or at any time after Delivery. Each invoice shall quote the
relevant Order Numbers. 

  

	10.2	 Biodesix shall pay invoices in full within 30 days of the date of receipt of invoice. Payment shall be made to
the bank account nominated in writing by Oncimmune in U.S. Dollars. 

  

	10.3	 If a party fails to make any payment due to the other under this Agreement by within [***] days of the due date
for payment, then, without limiting the other party’s other remedies hereunder, the defaulting party shall pay interest on the overdue amount at the rate of [***] per annum above Bank of England’s base rate from time to time. Such interest
shall accrue on a daily basis from the due date until the date of actual payment of the overdue amount, whether before or after judgment. The defaulting party shall pay the interest together with the overdue amount. In relation to payments disputed
in good faith, interest under this clause is payable only after the dispute is resolved, on sums found or agreed to be due, from [***] days after the dispute is resolved until payment. 

  
 7 

	10.4	 If Biodesix disputes any invoice or other statement of monies due, Biodesix shall promptly notify Oncimmune in
writing. The parties shall negotiate in good faith to attempt to resolve the dispute promptly. Oncimmune shall provide all such evidence as may be reasonably necessary to verify the disputed invoice or request for payment. If the parties have not
resolved the dispute within [***] days of Biodesix giving notice to Oncimmune, the dispute shall be resolved in accordance with clause 21. Where only part of an invoice is disputed, the undisputed amount shall be paid on the due date as set out in
clause 10.2. Oncimmune’s obligations to supply the Products shall not be affected by any good faith payment dispute. 

  

	10.5	 No party may set off any amounts owed to it by the other party under this Agreement against any amounts payable
by it to the other party under this Agreement (or otherwise). 

  

	10.6	 All undisputed payments payable to Oncimmune or Biodesix under this Agreement shall become due immediately on
its termination and any disputed payments determined to be due shall be paid within 30 days of such determination. This clause 10.6 is without prejudice to any right to claim for interest under law or under this Agreement. 

 

	11.	 COMPLIANCE 

In performing its obligations under the Agreement, each party shall comply with all applicable laws, statutes and regulations from time to time
in force. 
  

	12.	 INDEMNITY 

 

	12.1	 Oncimmune shall defend, hold harmless and indemnify Biodesix and its Affiliates, and its and their agents,
directors, officers and employees (the “Biodesix Indemnitees”) from and against any and all claims, suits, actions, demands, liabilities, expenses or losses, including reasonable legal expense and attorneys’ fees (collectively,
“Losses”), to which any Biodesix Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (each, a “Third-Party Claim”) to the extent such Losses arise out of:
(i) the failure of any Product to meet its written specifications, (ii) the infringement or misappropriation of any Third Party intellectual property rights by or on behalf of Oncimmune in the manufacture and supply of Product under this
Agreement or (iii) Oncimmune’s gross negligence or more culpable act or omission (including willful misconduct); except, in each case of (i) – (iii), to the extent of any Losses for which Biodesix is required to defend, hold
harmless and indemnify any or all Oncimmune Indemnitees under this Agreement or any other agreement between the parties hereto. 

  

	12.2	 Subject to the terms and conditions of this Agreement, including those set forth in clause 12.4, Biodesix shall
indemnify, defend and hold harmless Oncimmune and its officers, directors, employees, agents, Affiliates, successors and permitted assigns (Oncimmune Indemnitees) against any and all Losses incurred by such Oncimmune Indemnitees, relating
to/arising out of or resulting from any Claim to the extent such Losses arise out of: (i) breach or non-fulfillment by Biodesix of any of its representations, warranties,

  
 8 

	 	
covenants or agreements in this Agreement; or (ii) the commercialization, marketing, distribution, sale, use or performance of the Product or other operations of the Business (as defined in
the APA); except, in each case of (i) or (ii), to the extent of any Losses for which Oncimmune is required to defend, hold harmless and indemnify any or all Biodesix Indemnitees under this Agreement or any other agreement between the parties
hereto. 

  

	12.3	 In the event a party recovers damages in respect of a claim under an agreement between the parties hereto
related to the transactions contemplated hereby, (i) no other party will be entitled to recover with respect to the same claim and (ii) such party which recovers damages shall be barred from recovery with respect to the same claim under
any other agreement between the parties hereto related to the transactions contemplated hereby. 

  

	12.4	 Claims under clauses 12.1 and 12.2 shall be administered as provided for claims for indemnification under the
provisions of Section 9.3 of the APA. 

  

	12.5	 Notwithstanding anything to the contrary in this Agreement, neither party is obligated to indemnify or defend
any indemnified party against any Claim (whether direct or indirect) if such Claim or corresponding Losses directly result from such party’s or its Personnel’s gross negligence or more culpable act or omission (including wilful misconduct)
or bad faith failure to materially comply with any of its obligations set forth in this Agreement. 

  

	12.6	 If a payment due from either party under this clause is subject to tax (whether by way of direct assessment or
withholding at its source), the indemnified party shall be entitled to receive from such party such amounts as shall ensure that the net receipt, after tax, to the indemnified party in respect of the payment is the same as it would have been were
the payment not subject to tax. Notwithstanding the foregoing, this clause shall not apply to any income or corporation tax. 

  

	12.7	 Nothing in this clause shall restrict or limit either party’s general obligation at law to mitigate a loss
which it may suffer or incur as a result of a matter that may give rise to a claim under this indemnity. 

  

	12.8	 Except with respect to Claims alleging fraud, this clause 12 sets forth the entire liability and obligation of
each party and the sole and exclusive remedy for each indemnitee for any Losses covered by this clause 12. 

  

	13.	 LIMITATION OF LIABILITY 

 

	13.1	 Except for with respect to Claims alleging fraud, breach of clause 2.2, clause 10 or clause 11 or either
party’s indemnification obligations under clause 12.1 or 12.2 (to the extent such damages are required to be paid to a third party), neither party nor its Representatives will have any liability for any indirect or punitive damages, arising out
of or relating to any breach of this Agreement, whether or not the possibility of such damages has been disclosed in advance or could have been reasonably foreseen, regardless of the legal or equitable theory (contract, tort or otherwise) upon which
the claim is based, and notwithstanding the failure of any agreed or other remedy of its essential purpose, except any such damages that have been awarded to a third party. 

  
 9 

	14.	 ASSIGNMENT 

 

	14.1	 Either party may assign this Agreement only in connection with an assignment by such party of the PCA, as
permitted thereunder. 

  

	15.	 COMMENCEMENT AND TERM 

This Agreement shall commence on the Closing Date and shall expire or terminate upon the expiration or termination of the PCA (the Term). 

 

	16.	 OBLIGATIONS ON TERMINATION 

 

	16.1	 Upon termination, each party shall promptly return to the other party all equipment, materials and property
belonging to the other party that the other party had supplied to it or any of its affiliates in connection with the supply of the Product under this Agreement. 

 

	17.	 CONSEQUENCES OF TERMINATION 

 

	17.1	 On termination of this Agreement the following clauses shall survive and continue in full force and effect:

  

	 	17.1.1	 Clause 12 (Indemnity); 

 

	 	17.1.2	 Clause 13 (Limitation of liability); 

 

	 	17.1.3	 Clause 16 (Obligations on termination); 

 

	 	17.1.4	 Clause 17 (Consequences of termination); 

 

	 	17.1.5	 Clause 21 (Dispute resolution); and 

 

	 	17.1.6	 Clause 28 (Governing law and jurisdiction). 

 

	17.2	 Termination of this Agreement shall not affect any rights, remedies, obligations or liabilities of the parties
that have accrued up to the date of termination, including the right to claim damages in respect of any breach of the Agreement which existed at or before the date of termination. 

 

	18.	 FORCE MAJEURE 

 

	18.1	 The rights and obligations of the parties with respect to Force Majeure events in the PCA shall apply to the
rights and obligations of the parties under this Agreement. 

  

	19.	 COSTS 

Except as expressly provided in this Agreement, each party shall pay its own costs incurred in connection with the negotiation, preparation,
and execution of this Agreement. 

  
 10 

	20.	 SEVERABILITY 

 

	20.1	 If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of
competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. All remaining portions shall remain in full
force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. 

  

	21.	 DISPUTE RESOLUTION PROCEDURE 

 

	21.1	 If a dispute arises out of or in connection with this Agreement or the performance, validity or enforceability
of it, then the parties shall follow the procedures set out with respect to disputes in the PCA. 

  

	22.	 FURTHER ASSURANCE 

At its own expense, each party shall, and shall use commercially reasonable efforts to ensure that any necessary third party shall, promptly
execute and deliver such documents and perform such acts as may reasonably be required for the purpose of giving full effect to this Agreement. 
  

	23.	 VARIATION 

 

	23.1	 This Agreement (including the schedules hereto) is both a final expression of the Parties’ agreement and a
complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous Agreements and communications, whether oral, written or otherwise, concerning any and all matters contained herein. For
clarity, this Agreement does not supersede the PCA or other related transaction agreements. The schedules to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term
hereof modified, only by a written instrument duly executed by authorized representatives of both parties hereto. Each party acknowledges that in entering into this Agreement it does not rely on any statement, representation, assurance or warranty
(whether made innocently or negligently) that is not set out in this Agreement. 

  

	24.	 WAIVER 

 

	24.1	 The failure of a party to insist upon strict performance of any provision of this Agreement or to exercise any
right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a party of a particular provision or
right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. 

  
 11 

	25.	 NOTICES 

 

	25.1	 Any notice given to a party under or in connection with this Agreement shall be in writing and shall be as
provided for in the APA. 

  

	26.	 THIRD PARTY RIGHTS 

 

	26.1	 This Agreement is neither expressly nor impliedly made for the benefit of any person other than those executing
it, except as otherwise provided in this Agreement with respect to Biodesix Indemnitees and Oncimmune Indemnitees. 

  

	27.	 COUNTERPARTS 

This Agreement may be executed in counterparts, each of which shall constitute an original and all of which, when taken together, shall
constitute one Agreement. Signatures provided by facsimile transmission or in portable document format (PDF) sent by electronic mail shall be deemed to be original signature. 

 

	28.	 GOVERNING LAW; JURISDICTION 

 

	28.1	 This Agreement shall be construed in accordance with, and governed in all respects by, the internal laws of the
State of Delaware (without giving effect to principles of conflicts of laws). Both parties consent to the non-exclusive personal jurisdiction of all U.S. federal and Delaware state courts sitting within the
territory of the U.S. District Court, District of Delaware, for resolving any disputes arising out of or in connection with this Agreement. 

  

	29.	 WAIVER OF JURY
TRIAL. THE PARTIES TO THIS AGREEMENT IRREVOCABLY WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, COUNTERCLAIM OR CROSS-COMPLAINT IN ANY ACTION OR OTHER PROCEEDING BROUGHT
BY ANY PARTY TO THIS AGREEMENT AGAINST ANY OTHER PARTY OR PARTIES TO THIS AGREEMENT WITH RESPECT TO ANY MATTER ARISING OUT OF, OR IN ANY WAY CONNECTED WITH OR RELATED TO THIS AGREEMENT OR ANY PORTION OF THIS AGREEMENT, WHETHER BASED UPON
CONTRACTUAL, STATUTORY, TORTUOUS OR OTHER THEORIES OF LIABILITY. EACH PARTY REPRESENTS THAT IT HAS CONSULTED WITH COUNSEL REGARDING THE MEANING AND EFFECT OF THE FOREGOING WAIVER OF ITS RIGHT TO A JURY TRIAL. 

  
 12 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives as of the Closing Date. 
  

			
	ONCIMMUNE LIMITED

 
			
		
	By:	 	 
	Name:	 	
	Title:	 	
	Address:	 	

  

			
	BIODESIX, INC. 
		
	By:	 	/s/ Robin Harper Cowie
	Name:	 	Robin Harper Cowie
	Title:	 	CFO
	Address:	 	

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]